智通财经APP获悉，嘉和生物-B(06998)逆市涨近10%。截至发稿，涨9.83%，报1.9港元，成交额183.56万港元。
消息面上，近日，嘉和生物与亿腾医药宣布达成合并协议。根据协议，亿腾医药将以反向收购的方式，成为嘉和生物的全资附属公司，并更名为“亿腾嘉和医药集团有限公司”。这是自香港交易所颁布18A规则以来，首次实现的创新药企反向收购案例，标志着亿腾医药在资本市场的又一重大突破。
据了解，通过整合嘉和生物的创新研发资源，亿腾医药将能够加速创新药物的研发和市场推广。特别是嘉和生物即将上市的CDK4/6抑制剂来罗西利，能与亿腾医药现有的HDAC抑制剂景助达形成联动效应，共同开拓更广阔的市场空间。除了在国内市场发力外，嘉和生物与亿腾医药还将目光投向了海外市场。嘉和生物与亿腾医药的合并，将为双方未来的海外市场拓展奠定坚实的基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.